Navigation Links
Receptos to Deliver Scientific Presentation at Digestive Disease Week 2012 about the Therapeutic Role of RPC1063 in Inflammatory Bowel Disease
Date:5/18/2012

SAN DIEGO, May 18, 2012 /PRNewswire/ -- Receptos Inc. today announced that company personnel will deliver a scientific podium presentation about RPC1063 at the Digestive Disease Week (DDW) annual meeting at 9 a.m. PDT on Sunday, May 20, 2012 at the San Diego Convention Center in San Diego, California. DDW attracts thousands of physicians, researchers, and academics from around the world to share the latest research in gastrointestinal health topics, for which DDW is the premier scientific conference. Based on an abstract entitled "A small molecule S1P1 receptor agonist with significant efficacy in animal models of inflammatory bowel disease (IBD)," Receptos scientific personnel will discuss positive preclinical data with RPC1063 in two distinct in vivo models of IBD.

"Based on exciting data from these preclinical studies, as well as data from a recently completed Phase 1 clinical safety study, Receptos will initiate a Phase 2 clinical trial with RPC1063 in 2012 in inflammatory bowel disease," said Faheem Hasnain, President and Chief Executive Officer of Receptos. "The acceptance of these preclinical efficacy data for presentation at DDW underscores the need for efficacious oral treatments for the therapeutic treatment of IBD and the excitement on the part of scientific and clinical investigators to explore the novel profile of RPC1063 in patients suffering from this debilitating disease."

About RPC1063 and S1P1 Agonists
RPC1063 is a novel, differentiated sphingosine 1-phosphate 1 receptor (S1P1) selective agonist exhibiting picomolar potency that is effective in rodent models of both multiple sclerosis (MS) and inflammatory bowel disease (IBD), and possesses an excellent safety profile in non-clinical toxicology studies. Receptos has completed a Phase 1 clinical safety study with RPC1063 under a US IND that supports the desired differentiation profile and establishes justification for initiation of MS and IBD clinical efficacy
'/>"/>

SOURCE Receptos Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Receptos Achieves Milestone Under License of G-Protein Coupled Receptor Crystal Structure Determination Technology
2. Ceregene Parkinsons Disease Study Demonstrates Long-term Neurturin Expression and Enhanced Dopamine Activity 4 Years Following Delivery of CERE-120 (AAV2-neurturin)
3. AXIOS™ Stent and Delivery System Study Demonstrates Successful Treatment of Pancreatic Pseudocysts and Acute Cholecystitis
4. Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth
5. West Physics Consulting Teams with Mirion Technologies Dosimetry Services Division to Deliver Radiation Detection Services
6. Sustained Growth Forecast for Medical Devices and Drug Delivery Markets According to New Market Research Available from Global Information Inc.
7. VICAMs New Fumo-V Strip Tests Delivers Accurate Detection of Fumonisin Mycotoxins in Minutes
8. FDA Clears Expanded Compatibility for INOMAX® Drug-Delivery Systems
9. BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its Annual Report
10. Medical Device Study Delivers Marketing Budget and Staffing Metrics to Promote Efficient Use of Resources
11. Delcath Announces Agreement With Institut Gustave Roussy for Launch of Hepatic CHEMOSAT Delivery System in France
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... 2015 Research and Markets ( ... "Telemedicine and Mobile Healthcare Solutions, Services, and ... report to their offering. ... terms that pertain to the use of telecommunications ... clinical/non-clinical healthcare services. They form the ecosystem that ...
(Date:3/3/2015)... RADNOR, Pa. , March 3, 2015 /PRNewswire/ ... of laboratory products, services and solutions, announced today ... England Biolabs®, Inc. (NEB®). This agreement allows VWR ... renowned technical support in the U.S. and Puerto ... to NEB,s products through VWR,s e-business platform, sales ...
(Date:3/3/2015)... BETHESDA, Md. , March 3, 2015 /PRNewswire/-- ViaCyte, Inc., ... cell-derived islet replacement therapy for the treatment of diabetes ... Eugene Brandon , Director of Strategic Relations and ... summit showcases the latest in type 1 diabetes management ... are as follows: , , , Title:   ...
Breaking Medicine Technology:Global Telemedicine and Mobile Healthcare Solutions, Services, and Devices: Market Analysis and Forecasts 2015 - 2020 2Global Telemedicine and Mobile Healthcare Solutions, Services, and Devices: Market Analysis and Forecasts 2015 - 2020 3VWR Announces Expansion of Distribution Agreement with New England Biolabs 2ViaCyte to Present at JDRF TypeOneNation Research Summit 2
(Date:3/4/2015)... Professionals with disabilities are eager to ... companies, according to a new Think Beyond the Label ... 235 professionals with disabilities , respondents also say they ... including ones that are geared to people with disabilities, ... ,     Online job search tools are used by ...
(Date:3/4/2015)... 04, 2015 The medical device landscape ... management forgot – or ignored or didn't know – ... market based on physician input before proceeding to design ... specifically, founders – become so enamored of an innovative ... Will physicians use the device?” says Dr. Kathryn ...
(Date:3/3/2015)... Anik Singal's Profit Academy - ... marketers has become the talk of the town ... surrounding the course's general release has garnered the ... her to review the program's content and publish ... biggest keys to success with Internet marketing is ...
(Date:3/3/2015)... March 03, 2015 On February 21st, ... the fabulous EcoLuxe Lounge, a day-long event that features ... conscious products and services. Organized by Debbie Durkin and ... film placement producer, the EcoLuxe Lounge saw many notable ... roles on General Hospital, The Flash, Star Trek: Deep ...
(Date:3/3/2015)... March 03, 2015 Findings could lead ... at UC Davis have developed and characterized a molecule ... causing them to self-destruct. This novel mechanism was found ... a usually fatal type of brain cancer – and ... , The article, to be published in the April ...
Breaking Medicine News(10 mins):Health News:Job Seekers with Disabilities Seek Targeted Outreach from Employers and Online Job Search Tools, says New Think Beyond The Label Survey 2Health News:Job Seekers with Disabilities Seek Targeted Outreach from Employers and Online Job Search Tools, says New Think Beyond The Label Survey 3Health News:Want to Succeed in Medical Technology? Don't Innovate in a Vacuum 2Health News:Want to Succeed in Medical Technology? Don't Innovate in a Vacuum 3Health News:Anik Singal's Profit Academy - Review Of New IM Training Program Released 2Health News:Hollywood Star Chase Masterson and Choices Recovery Discuss Substance Abuse and Treatment at 2015 Oscars 2Health News:News: UC Davis Scientists Describe Novel Drug Mechanism That Fights Brain Cancer 2Health News:News: UC Davis Scientists Describe Novel Drug Mechanism That Fights Brain Cancer 3Health News:News: UC Davis Scientists Describe Novel Drug Mechanism That Fights Brain Cancer 4
... could actually be caused as a result of a defect ... after scientists have worked towards identifying important skin cancer genes ... scientists to look at thousands of genes at once, helping ... greater detail. There are over 200 different types of cancer ...
... ketoacidosis (DKA) is a life-threatening condition that frequently ... The critical factors in the treatment of DKA ... skillful fluid and electrolyte adjustment, and the initiation ... fluid volume has been achieved. Continuous low-dosage intravenous ...
... Anderson Cancer Center have found that weight gain or ... of prostrate cancer. ,The report is detailed in ... Research, corroborates findings of an earlier research that had ... Strom, Ph.D., an associate professor in the Department of ...
... Phase II study to 12 months confirm the significant effects ... patients with relapsing multiple sclerosis (MS). ,The data, ... both patient groups taking FTY720 (1.25 mg and 5 mg) ... of more than 50% during the first six months of ...
... chronic illness that requires continuing medical care and ... to reduce the risk of long-term complications//. As ... care practitioners are confronted with an ever-increasing tide ... Undiagnosed chronic kidney disease (CKD) is common in ...
... an ancient myth that coco bean can be used to treat ... limit the development of fluids that cause diarrhea//. ,The use ... 16th century by ancient South American and European cultures. Until now, ... bean or more specifically why it has been used in the ...
Cached Medicine News:Health News:Novartis MS Drug Shows Promising Results 2Health News:Novartis MS Drug Shows Promising Results 3
... simple, effective method for determining color vision ... data which can be applied to many ... set consists of four trays containing a ... that have incremental hue variation on one ...
... D15 test evaluation has a choice ... caps with automatic creation 'horse-shoe' diagrams, ... deficiency analysis, calculation of color confusion ... eye selection (OD, OS, OU) and ...
... Farnsworth D15 test is used ... color defect vs normal. Farnsworth ... which permit the patient to ... Then the box is closed ...
HRR/Amsler book combo with occluding glasses....
Medicine Products: